Fig. 4
From: A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis
Production, binding kinetics, and biological activity of hAlb-CTLA4Ig. A Purity assessment of hAlb-CTLA4Ig by SDS-PAGE and Coomassie blue staining after purification of the recombinant proteins from the culture supernatant of ExpiCHO transfectants. B Cleavage of hAlb-CTLA4Ig by MMP2/9 (left panel) and MMP-3 (right panel) was assessed by western blot using a goat-anti human IgG antibody. C Binding kinetics of nondigested hAlb-CTLA4Ig (blue curve), MMP-digested (orange curve) hAlb-CTLA4Ig, or conventional hCTLA4Ig (black curve) were analyzed using cell-based ELISA. EC50 values are indicated with matching colors. D Schematic representation of the in vitro human T cell activation model in the current study. E Effects of nondigested hAlb-CTLA4Ig, MMP-digested hAlb-CTLA4Ig, or conventional hCTLA4Ig (all at 1 nM) on IL-2 secretion by Jurkat T cells. F Inhibition curves of Jurkat T cell activation by nondigested hAlb-CTLA4Ig (blue curve), MMP-digested hAlb-CTLA4Ig (orange curve), or conventional hCTLA4Ig (black curve). IC50 values are indicated by matching colors